Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization
- 18 May 2012
- journal article
- Published by Springer Nature in Eye
- Vol. 26 (7), 1004-1011
- https://doi.org/10.1038/eye.2012.97
Abstract
Purpose Methods Results ConclusionsKeywords
This publication has 37 references indexed in Scilit:
- NON–FULL-THICKNESS MACULAR HOLES REASSESSED WITH SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHYRetina, 2012
- PREDICTIVE FACTORS FOR VISUAL OUTCOME TO INTRAVITREAL BEVACIZUMAB IN YOUNG CHINESE PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2011
- Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularizationJapanese Journal of Ophthalmology, 2011
- DIFFERENT DOSING OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION BECAUSE OF PATHOLOGIC MYOPIARetina, 2011
- Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularizationEye, 2011
- TWELVE-MONTH OUTCOME AFTER ONE INTRAVITREAL INJECTION OF BEVACIZUMAB TO TREAT MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- MACULAR FUNCTIONAL CHANGES EVALUATED WITH MP-1 MICROPERIMETRY AFTER INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- INTRAVITREAL ANTI-VEGF VERSUS PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATIONRetina, 2010
- Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaBritish Journal of Ophthalmology, 2007
- Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopiaBritish Journal of Ophthalmology, 2007